AstraZeneca: Squamous Cell Carcinoma of Head and Neck trials
The registry lists 22 Squamous Cell Carcinoma of Head and Neck studies with AstraZeneca as lead sponsor. 4 are open to participants now and 6 have results posted.
Phase 1 13Phase 2 8Phase 3 4No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsRecruitingNCT07115043Phase 1/2
- Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid TumorsRecruitingNCT06535607Phase 2
- A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent ChemoradiotherapyRecruitingNCT06129864Phase 3
- A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationRecruitingNCT05877599Phase 1
- Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck CancerActive, not recruitingNCT04590963Phase 3Results posted
- Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck CancerCompletedNCT03162224Phase 1/2Results posted
- Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck CancerCompletedNCT02551159Phase 3Results posted
- Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & NeckCompletedNCT02499328Phase 1/2Results posted
- Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell CarcinomaCompletedNCT02454179Phase 2Results posted
- IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT00229723Phase 2Results posted
- A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursActive, not recruitingNCT06147037Phase 1
- A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid TumoursTerminatedNCT05363605Phase 1/2
- A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid TumorsCompletedNCT03811652Phase 1
- A Phase 1 Study of [225Ac]-FPI-1434 InjectionTerminatedNCT03746431Phase 1
- Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid TumorsCompletedNCT03509012Phase 1
- A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).CompletedNCT03022409Phase 1
- Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsCompletedNCT02658214Phase 1
- SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)CompletedNCT02543476
- A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck CancerCompletedNCT02262741Phase 1
- A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid TumoursCompletedNCT01938612Phase 1
- Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT00233636Phase 2
- Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)CompletedNCT00206219Phase 3